Pharma BD Deal Intelligence
Sobi buys into a first-in-class KIR3DL2 antibody at the confirmatory-trial stage
Full analysis, sources & comparables →Sobi and Innate Pharma entered a strategic partnership under which Sobi licenses lacutamab, an anti-KIR3DL2 monoclonal antibody, in T-cell lymphoma. Sobi pays Innate USD 75 million on closing, with up to a further USD 40 million in near-term development milestones tied to Sezary syndrome and up to USD 465 million linked to Sobi's option for full development rights plus future regulatory and commercial milestones, for a headline value of up to USD 580 million, alongside tiered double-digit royalties on net sales. Innate will run the TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma supporting a planned accelerated approval filing in Sezary syndrome; Sobi receives exclusive global commercialization rights upon potential accelerated approval and may assume full global development rights after positive Phase 3 results.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Swedish Orphan Biovitrum AB / Innate Pharma SA (this deal) | 2026 | $580M | 68 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| Swedish Orphan Biovitrum AB / CTI BioPharma Corp. | 2023 | $1.7B | 60 |
| Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. | 2025 | $1.5B | — |
| Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. | 2020 | $1.0B | — |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |